Great research. But now I'll have my usual rant based on a quote from the article:
>> Findings from this study, in conjunction with future work on SVV-antibody interaction sites, can provide a promising stage for the development of SVV mutants with improved clinical applications.
In this case "improved clinical applications" means man-made variations that can be patented. I mean, why wait? Sure go ahead and try to improve on it, but in the mean time isn't it recommended for trials (in addition to other treatments) against certain cancers? Or is it and I'm just not aware?
>> Findings from this study, in conjunction with future work on SVV-antibody interaction sites, can provide a promising stage for the development of SVV mutants with improved clinical applications.
In this case "improved clinical applications" means man-made variations that can be patented. I mean, why wait? Sure go ahead and try to improve on it, but in the mean time isn't it recommended for trials (in addition to other treatments) against certain cancers? Or is it and I'm just not aware?